Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 404Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Multi-regional clinical trials and global drug development

Shenoy Premnath

Year : 2016| Volume: 7| Issue : 2 | Page no: 62-67

   This article has been cited by
1 Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics
Sunita Panda, Puneet Kumar Singh, Snehasish Mishra, Sagnik Mitra, Priyabrata Pattnaik, Sanjib Das Adhikary, Ranjan K. Mohapatra
Vaccines. 2023; 11(1): 110
[Pubmed]  [Google Scholar] [DOI]
2 Ethical Considerations in Clinical Trials for Disorders of Consciousness
Michael J. Young, Yelena G. Bodien, Brian L. Edlow
Brain Sciences. 2022; 12(2): 211
[Pubmed]  [Google Scholar] [DOI]
3 Regional efficacy evaluation in multi-regional clinical trials using a discounting factor weighted Z test
Xuanxuan Yu, Lixin Cai, Hao Yu, Zihang Zhong, Min Yang, Jingwei Wu, Jianling Bai
Pharmaceutical Statistics. 2022;
[Pubmed]  [Google Scholar] [DOI]
4 Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
Jenn W. Sellers, Camelia M. Mihaescu, Kassa Ayalew, Phillip D. Kronstein, Bei Yu, Yang-Min Ning, Miguel Rodriguez, LaKisha Williams, Ni A. Khin
Therapeutic Innovation & Regulatory Science. 2022;
[Pubmed]  [Google Scholar] [DOI]
5 A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
Yuko Hoshino, Mamoru Narukawa
Therapeutic Innovation & Regulatory Science. 2022;
[Pubmed]  [Google Scholar] [DOI]
6 Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials
Marie-Noëlle Billard, Joanne Wildenbeest, Louis J. Bont, Harish Nair, John P. McCracken, Katrien Oude Rengerink, Marie-Noelle Billard, Katrien Oude Rengerink, Louis Bont, Joanne Wildenbeest, Harish Nair, Harry Campbell, Philippe Beutels, Peter Openshaw, Andrew Pollard, Federico Martinon-Torres, Terho Heikkinen, Adam Meijer, Thea Křlsen Fischer, Maarten van den Berge, Carlo Giaquinto, Jeroen Aerssens, Michael Abram, Kena Swanson, Clarisse Demont, Scott Gallichan, Veena Kumar, Sonia Stoszek, Eva Molero
Journal of Clinical Epidemiology. 2022; 147: 11
[Pubmed]  [Google Scholar] [DOI]
7 Design and Implementation of Medical Searching System Based on Microservices and Serverless Architectures
Jawad Sadek, Dawn Craig, Michael Trenell
Procedia Computer Science. 2022; 196: 615
[Pubmed]  [Google Scholar] [DOI]
8 Machine Learning Prediction of Clinical Trial Operational Efficiency
Kevin Wu, Eric Wu, Michael DAndrea, Nandini Chitale, Melody Lim, Marek Dabrowski, Klaudia Kantor, Hanoor Rangi, Ruishan Liu, Marius Garmhausen, Navdeep Pal, Chris Harbron, Shemra Rizzo, Ryan Copping, James Zou
The AAPS Journal. 2022; 24(3)
[Pubmed]  [Google Scholar] [DOI]
9 Lag Time for New Innovative, First-in-Class, Drug Approval in Japan
Takayuki Miyazaki, Michiyuki Komiyama, Naoki Matsumaru, Hideki Maeda, Katsura Tsukamoto
Biological and Pharmaceutical Bulletin. 2022; 45(4): 477
[Pubmed]  [Google Scholar] [DOI]
10 Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials
Satoshi Ushijima,Naoki Matsumaru,Katsura Tsukamoto
Pharmaceutical Medicine. 2021;
[Pubmed]  [Google Scholar] [DOI]
11 A Cross-sectional literature survey showed the reporting quality of multicentre randomised controlled trials should be improved
Xuan Zhang,Wai Ching Lam,Fan Liu,Mengdan Li,Lin Zhang,Weifeng Xiong,Xiaohan Zhou,Ran Tian,Chongya Dong,Chen Yao,David Moher,Zhaoxiang Bian
Journal of Clinical Epidemiology. 2021;
[Pubmed]  [Google Scholar] [DOI]
12 The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, Luís Alberto Bręda Mascarenhas, Leone Peter Correia da Silva Andrade, Vinícius Pinto Costa Rocha, Milena Botelho Pereira Soares, Peter Berglund, Malcolm S. Duthie, Steven G. Reed, Roberto Badaró
Vaccines. 2021; 9(11): 1345
[Pubmed]  [Google Scholar] [DOI]
13 Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality
Teodora Lalova,Cristina Padeanu,Anastassia Negrouk,Denis Lacombe,Jan Geissler,Ingrid Klingmann,Isabelle Huys
Frontiers in Medicine. 2020; 7
[Pubmed]  [Google Scholar] [DOI]
14 The progression of clinical trials in Indonesia: An observational study of records from clinical trial registries databases
Marlinang Diarta Siburian,Sifa Marie Joelle Muchanga,Antonio Fredelindo Dela Resma Villanueva,Rianto Setiabudy,Iiyama Tatsuo
Global Health Journal. 2020;
[Pubmed]  [Google Scholar] [DOI]
15 A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates
Jonathan Dando,Maximilian Lebmeier
Journal of Innovation and Entrepreneurship. 2020; 9(1)
[Pubmed]  [Google Scholar] [DOI]
16 Hierarchical Generalized Linear Models for Multi-Regional Clinical Trials
Junhui Park,Seung-Ho Kang
Statistics in Biopharmaceutical Research. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
17 Strategic inclusion of regions in multiregional clinical trials
Seung Yeon Song,Deborah Chee,EunYoung Kim
Clinical Trials. 2019; 16(1): 98
[Pubmed]  [Google Scholar] [DOI]
18 Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016
Yao Qiao,G Caleb Alexander,Thomas J Moore
Clinical Trials. 2019; 16(3): 329
[Pubmed]  [Google Scholar] [DOI]
19 Perspectives on Adopting the Guideline for Multi-regional Clinical Trials in Korea: A Multi-stakeholder Survey
Minji Sohn,Yun-Kyoung Song,Ah Young Jeon,Jung Mi Oh,In-Wha Kim
Korean Journal of Clinical Pharmacy. 2019; 29(4): 267
[Pubmed]  [Google Scholar] [DOI]
20 Acceleration of rare disease therapeutic development: a case study of AGIL-AADC
Sonya Das,Samuel Huang,Andrew W. Lo
Drug Discovery Today. 2019;
[Pubmed]  [Google Scholar] [DOI]
21 Cell-Based Therapies for Stroke: Are We There Yet?
Mirja Krause,Thanh G. Phan,Henry Ma,Christopher G. Sobey,Rebecca Lim
Frontiers in Neurology. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
22 Investigator-initiated clinical trials in the Czech Republic - overview for 2004-2007
Lenka Horavová,Katerina Nebeská,Jana Merhautová,Regina Demlová,Lenka Soucková
Klinická farmakologie a farmacie. 2019; 32(4): 3
[Pubmed]  [Google Scholar] [DOI]
23 Comparative evidence on harms in pediatric randomized clinical trials from less developed versus more developed countries is limited
Dario Tedesco,Mufiza Farid-Kapadia,Martin Offringa,Zulfiqar A. Bhutta,Yvonne Maldonado,John P.A. Ioannidis,Despina G. Contopoulos-Ioannidis
Journal of Clinical Epidemiology. 2018; 95: 63
[Pubmed]  [Google Scholar] [DOI]
24 Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan
Mitsuhiro Rokuda,Naoki Matsumaru,Katsura Tsukamoto
Clinical Therapeutics. 2018;
[Pubmed]  [Google Scholar] [DOI]
25 Regulations and Guidelines for Planning and Design of Multi-regional Clinical Trials
Yun-Kyoung Song,Minji Sohn,Ah Young Jeon,Jae Hyun Kim,Eunhee Ji,Jung Mi Oh,In-Wha Kim
Korean Journal of Clinical Pharmacy. 2018; 28(2): 146
[Pubmed]  [Google Scholar] [DOI]


Read this article